Skip to main content

New direction for treating lung cancer

Feb. 7, 2014, 8:00 AM

(iStock)

Non-small cell lung cancer (NSCLC) accounts for about 85 percent of all lung cancer cases and has a high mortality rate, underscoring the need for new treatments. Ambra Pozzi, Ph.D., and colleagues report in the Jan. 15 issue of Cancer Research that activation of the protein PPAR-alpha represents a new avenue for treating NSCLC growth and progression.

The investigators previously showed that activation of PPAR-alpha reduces the expression of the P450 enzyme Cyp2c44 and its production of lipids that promote blood vessel development (angiogenesis). They now demonstrate in two mouse models that PPAR-alpha activators reduce primary and metastatic NSCLC growth and that these effects are associated with a reduction in Cyp2c44 expression and in the levels of its pro-angiogenic products.

The findings suggest that strategies to reduce Cyp2c expression and/or activity – including activation of PPAR-alpha – may offer new treatment options for NSCLC. One of the tested PPAR-alpha activators (bezafibrate) is already approved for lipidemia and could be quickly evaluated for its potential in lung cancer.

This research was supported by the VA Merit Review Award Program, the National Institutes of Health (CA162433, DK095761, DK083187, DK075594, DK069221, DK038226), and the NCI SPORE in Lung Cancer (CA090949).

Send suggestions for articles to highlight in Aliquots and any other feedback about the column to aliquots@vanderbilt.edu

Recent Stories from VUMC News and Communications Publications

Marissa Benchea has CF, and she is one of hundreds of thousands of adults not only surviving but thriving with a chronic childhood disease.

Vanderbilt Medicine

Marissa Benchea has CF, and she is one of hundreds of thousands of adults not only surviving but thriving with a chronic childhood disease.

One hundred years ago, multiple “waves” of a deadly flu swept across the world.

Vanderbilt Medicine

One hundred years ago, multiple “waves” of a deadly flu swept across the world.

A diagnosis of cancer at any age is tragic, but during the adolescent and young adult years, it’s especially complicated.

Hope

A diagnosis of cancer at any age is tragic, but during the adolescent and young adult years, it’s especially complicated.

Karen Dyer Young cares for patients and members of the Dayani Center who have or are recovering from cancer or a stem cell transplant.

Momentum

Karen Dyer Young cares for patients and members of the Dayani Center who have or are recovering from cancer or a stem cell transplant.

more